Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
January 24, 2019 6:59 AM ESTIncreases Fourth Quarter Revenues 10% to $6.0 Billion, 9% for Full Year to $22.6 Billion Posts Fourth Quarter GAAP EPS of $0.73 and Non-GAAP EPS of $0.94 Announces Strategic Acquisition of Celgene Corporation Announces Voluntary Withdrawal of U.S. Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Lung Cancer in Patients with Tumor Mutational Burden 10 Mutations/Megabase, following discussions with the U.S. FDA Additional Opdivo Plus Yervoy Approvals in Europe for Patients with Renal Cell Carcinoma... More
